Nektar Therapeutics

Nektar Therapeutics secured a jury verdict of $90 million in damages against Eli Lilly and Company for breach of the implied covenant of good faith and fair dealing related to their prior collaboration agreement.

Nektar Therapeutics has announced a quiet period effective September 8, 2026, leading up to the public release of data from its Phase 2b REZOLVE-AA study.

Nektar Therapeutics shareholders approved the election of a director, an increase in incentive plan shares, and the ratification of auditors at the 2026 Annual Meeting.

Nektar Therapeutics has entered into an equity distribution agreement to sell up to $150 million of its common stock through an at-the-market offering program.

Nektar Therapeutics announced the pricing of an upsized public offering of $325 million of its common stock, with net proceeds expected to be approximately $350.9 million.

Nektar Therapeutics announced a cash and marketable securities balance of approximately $741.7 million as of April 1, 2026.

Nektar Therapeutics reported a reduced net loss in Q3 2025, driven by lower operating expenses, while advancing its lead immunotherapy candidates and securing significant capital.

Nektar Therapeutics reported a reduced quarterly net loss and positive Phase 2b data for rezpegaldesleukin, while securing significant capital post-period.

Nektar Therapeutics announces its Q1 2025 financial results, detailing a net loss of $50.88 million and highlighting the progress of its clinical programs, particularly rezpegaldesleukin.

Nektar Therapeutics' Q3 2024 report details financial results, strategic updates, and progress in clinical development programs, including the sale of its manufacturing facility.

Nektar Therapeutics' second quarter 2024 results reflect ongoing strategic reorganization and cost restructuring efforts, with a focus on advancing key drug candidates.

Nektar Therapeutics announced its first quarter 2024 financial results, emphasizing advancements in its rezpegaldesleukin and NKTR-255 clinical programs and strategic financial maneuvers.

Nektar Therapeutics details its 2024 financial performance and provides updates on its key drug development programs, including rezpegaldesleukin and NKTR-255.

Nektar Therapeutics' 2023 annual report highlights a strategic shift towards immunotherapy, focusing on key drug candidates and cost restructuring efforts.

Roy A Whitfield, a Director of Nektar Therapeutics, reported multiple transactions in common stock on September 23, 2026.

R Scott Greer, a Director of Nektar Therapeutics, reported multiple transactions in common stock on September 23, 2026.

Robert Chess, a Director of Nektar Therapeutics, reported multiple transactions in common stock on September 23, 2026.

Diana Brainard, a Director of Nektar Therapeutics, reported multiple transactions in common stock on September 23, 2026.

Jeffrey Robert Ajer, a Director of Nektar Therapeutics, reported multiple transactions in common stock on September 23, 2026.

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 186 shares of common stock on August 18, 2026 for $71.98 per share.

Nektar Therapeutics has issued its 2026 proxy statement, seeking shareholder approval for director election, an increase in equity plan shares, and executive compensation.

Nektar Therapeutics is asking stockholders to vote on several proposals at its upcoming annual meeting, including a reverse stock split, an increase in authorized shares, and amendments to its incentive plan.

Nektar Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission.

Nektar Therapeutics is holding its annual stockholder meeting on June 5, 2024, to vote on director elections, an amendment to the performance incentive plan, ratification of the accounting firm, and executive compensation.

Two Seas Capital LP, along with its affiliates, has disclosed beneficial ownership of 3,345,978 shares, representing 9.8% of Nektar Therapeutics' common stock.

Investment firm Two Seas Capital LP, along with its GP and CIO Sina Toussi, has disclosed beneficial ownership of 3,092,234 shares, representing 9.1% of Nektar Therapeutics' common stock as of June 30, 2026.

Several Biotechnology Value Funds have updated their beneficial ownership filings for Nektar Therapeutics, reporting a combined stake of 7.1% as of June 30, 2026.

Vanguard Capital Management has reported a beneficial ownership stake of 5.17% in Nektar Therapeutics, holding over 1.7 million shares.

Biotechnology Value Fund and associated entities have reported a 9.8% beneficial ownership stake in Nektar Therapeutics.

FMR LLC, through its subsidiaries, has reported beneficial ownership of 15.0% of Nektar Therapeutics' common stock as of March 31, 2026.